(RTTNews) - Orgenesis Inc. (ORGS), Thursday announced positive results from a real-world study of CD19 CAR-T therapy, ORG-101, in patients with CD19+ Acute Lymphoblastic Leukemia.
According to the company, ORG-101 uses a third-generation lentiviral vector with a proprietary CAR construct, along with streamlined and decentralized onsite production and analytic testing.
The real-world study revealed that ORG-101 achieved a complete response of 82 percent in adult patients and 93 percent in pediatric patients, with a low incidence of Cytokine Release Syndrome in both groups.
The biotech company plans to initiate its own Phase 1/2 clinical multicenter study at the General University Hospital of Patras in Greece.
Meanwhile, Harley Street Healthcare Group aims to set up a Global Cancer Initiative along with Orgenesis, focusing on democratizing Advance Therapies and supporting further clinical development.
Currently, Orgenesis's stock is trading at $0.70, up 0.77 percent on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
